Relatlimab
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Urethra Transitional Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cis-Diamminedichloroplatinum Ii Nagoya University | Phase 3 | BB |
Nivolumab Nagoya University | Phase 3 | BB |
Cyclophosphamide Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Pembrolizumab Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Atezolizumab Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 22 →
Same molecule, other indications
Relatlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →